XAIR Stock Summary and Trading Ideas (Beyond Air | NASDAQ:XAIR)

Beyond Air Inc a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems (the LungFit platform) capable of generating NO from ambient air. Its segments are Beyond Air, Beyond Cancer, and NeuroNos. The company generates majority of revenue from Beyond Air. It has developed the Beyond Air NO generator and delivery system which it call LungFit, a novel and precise delivery system that uses NO generated from ambient air with a novel NO generator, the ionizer. Its product and technology includes LungFitPH.

Beyond Air trades on the NASDAQ stock market under the symbol XAIR.

As of August 21, 2026, XAIR stock price declined to $5.04 with 22,976 million shares trading.

XAIR has a beta of -0.47, meaning it tends to be less sensitive to market movements. XAIR has a correlation of 0.00 to the broad based SPY ETF.

XAIR has a market cap of $4.96 million. This is considered a Sub-Micro Cap stock.

Last quarter Beyond Air reported $2 million in Revenue and -$11.00 earnings per share. This fell short of revenue expectation by $-161,000 and missed earnings estimates by -$.20.

In the last 3 years, XAIR traded as high as $1,339.20 and as low as $4.88.

The top ETF exchange traded funds that XAIR belongs to (by Net Assets): VXF.

XAIR has underperformed the market in the last year with a price return of -88.2% while the SPY ETF gained +21.2%. XAIR has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -37.3% and -9.4%, respectively, while the SPY returned +3.6% and -0.4%, respectively.

XAIR support price is $4.77 and resistance is $5.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XAIR shares will trade within this expected range on the day.